Literature DB >> 12605368

Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis.

Wataru Yoshida1, Miwa Uzuki, Akira Kurose, Masaaki Yoshida, Jun Nishida, Tadashi Shimamura, Takashi Sawai.   

Abstract

The aim of this study was to determine the histologic and cellular characteristics of 2 cell types, mononuclear cells (Mos) and multinuclear giant cells (GCs), that predominantly constitute pigmented villonodular synovitis (PVS). Synovial tissues examined in this study were obtained from 10 patients with PVS. Five methods were used for cell analysis: (1) enzyme-histochemistry for tartrate-resistant acid phosphatase (TRAP); (2) immunohistochemistry using antibodies for CD68, macrophage colony-stimulating factor (M-CSF), MIB-1, p53, p21, p16, and cathepsin-L (cath L); (3) TdT-mediated deoxyuridine triphosphate-biotin terminal end labeling (TUNEL) as a measure of apoptosis; (4) fluorescence-based polymerase chain reaction single-strand conformation polymorphism analyses (FPCR-SSCP) to detect p53 gene mutations; and (5) in situ hybridization using gene-specific oligoprobes for matrix metalloproteinase (MMP)-2, MMP-9, receptor activator of nuclear factor kappaB ligand (RANKL), and calcitonin receptor (CTR). Both Mos and GCs were shown to express the macrophage/histiocyte marker CD68. In GCs, TRAP and CTR, both of which are known as characteristic phenotype markers of osteoclasts, were expressed. M-CSF and RANKL, which are together essential for osteoclast differentiation, were expressed in both Mos and GCs. Mos were shown to express MIB-1, but GCs were not. Although proliferation-suppressor proteins p53, p21, and p16 were expressed in both Mos and GCs, little apoptotic phenomenon of lining Mos was detected by TUNEL. In our study, p53 gene mutations for exons 5, 7, and 8 in PVS synovial tissues were not detected by FPCR-SSCP analysis. Furthermore, both types of cells demonstrated the proteolytic enzymes MMP-2 and MMP-9 mRNA, and cath L protein. These results suggest that PVS has a hyperplastic property consisting of the CD68-positive monocytic cell lineage with differentiation of osteoclastic giant cells from monocyte and probably controlled against proliferation by wild-type p53, p21, and p16. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605368     DOI: 10.1053/hupa.2003.52

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors.

Authors:  Biqiang Zheng; Lin Yu; Jingying Hu; Huili Xu; Jian Wang; Yingqiang Shi; Xiaoying Luo; Wangjun Yan
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

2.  Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB.

Authors:  Teresa Morgan; Gerald J Atkins; Melanie K Trivett; Sandra A Johnson; Maya Kansara; Stephen L Schlicht; John L Slavin; Paul Simmons; Ian Dickinson; Gerald Powell; Peter F M Choong; Andrew J Holloway; David M Thomas
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

3.  Fine needle aspiration biopsy of an osteoclast-rich undifferentiated urothelial carcinoma: A cytology case report and review of the literature.

Authors:  Marilyn M Bui; Chetna N Purohit; Ardeshir Hakam
Journal:  Cytojournal       Date:  2010-09-17       Impact factor: 2.091

4.  Intraarticular adalimumab in a patient with pigmented villonodular synovitis.

Authors:  Senol Kobak
Journal:  Rheumatol Int       Date:  2009-10-10       Impact factor: 2.631

Review 5.  Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.

Authors:  Mehdi Brahmi; Armelle Vinceneux; Philippe A Cassier
Journal:  Curr Treat Options Oncol       Date:  2016-02

6.  Expression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis.

Authors:  Takehiro Ota; Hiroshi Urakawa; Eiji Kozawa; Kunihiro Ikuta; Shunsuke Hamada; Satoshi Tsukushi; Yoshie Shimoyama; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Tumour Biol       Date:  2015-02-18

7.  Surgical treatment for diffused-type giant cell tumor (pigmented villonodular synovitis) about the ankle joint.

Authors:  Xingchen Li; Yang Xu; Yuan Zhu; Xiangyang Xu
Journal:  BMC Musculoskelet Disord       Date:  2017-11-14       Impact factor: 2.362

8.  Pigmented villonodular synovitis: Four pediatric cases and brief review of literature.

Authors:  S Turkucar; B Makay; H Tatari; E Unsal
Journal:  J Postgrad Med       Date:  2019 Oct-Dec       Impact factor: 1.476

9.  Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.

Authors:  Marie Robert; Helena Farese; Pierre Miossec
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

10.  Cadherin-11 cooperates with inflammatory factors to promote the migration and invasion of fibroblast-like synoviocytes in pigmented villonodular synovitis.

Authors:  Chenxi Cao; Fei Wu; Xingyue Niu; Xiaoqing Hu; Jin Cheng; Yan Zhang; Chuanyun Li; Xiaoning Duan; Xin Fu; Jiying Zhang; Xin Zhang; Yingfang Ao
Journal:  Theranostics       Date:  2020-08-21       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.